Response to: 'Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis'' by Xu

被引：0
作者：
Mok, Chi Chiu [1 ]
机构：
[1] Tuen Mun Hosp, Dept Med & Geriatr, Hong Kong, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷 / 12期
关键词：
lupus nephritis; therapeutics; lupus erythematosus; systemic; POSTERIOR REVERSIBLE ENCEPHALOPATHY; ANTIPHOSPHOLIPID SYNDROME; ERYTHEMATOSUS;
D O I：
10.1136/annrheumdis-2020-219087
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 10 条
  • [1] Clinical features, outcome, and associated factors for posterior reversible encephalopathy in Thai patients with systemic lupus erythematosus: a case-control study
    Damrongpipatkul, Usanee
    Oranratanachai, Kanokporn
    Kasitanon, Nuntana
    Wuttiplakorn, Salita
    Louthrenoo, Worawit
    [J]. CLINICAL RHEUMATOLOGY, 2018, 37 (03) : 691 - 702
  • [2] Posterior reversible encephalopathy syndrome as a neuropsychiatric manifestation of systemic lupus erythematosus
    Ho, C. M.
    Mok, C. C.
    [J]. HONG KONG MEDICAL JOURNAL, 2019, 25 (05) : 410 - 412
  • [3] Posterior reversible encephalopathy syndrome in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome
    Jung, S. M.
    Moon, S-J
    Kwok, S-K
    Ju, J. H.
    Park, K-S
    Park, S-H
    Kim, H-Y
    [J]. LUPUS, 2013, 22 (09) : 885 - 891
  • [4] Antiphospholipid Syndrome Nephropathy and Other Thrombotic Microangiopathies Among Patients With Systemic Lupus Erythematosus
    Kotzen, Elizabeth S.
    Roy, Sanjeet
    Jain, Koyal
    [J]. ADVANCES IN CHRONIC KIDNEY DISEASE, 2019, 26 (05) : 376 - 386
  • [5] Clinical Features and Outcomes of Posterior Reversible Encephalopathy Syndrome in Patients With Systemic Lupus Erythematosus
    Lai, Chien-Chih
    Chen, Wei-Sheng
    Chang, Yu-Sheng
    Wang, Shu-Hung
    Huang, Chun-Jui
    Guo, Wan-Yuo
    Yang, Wu-Chang
    Huang, De-Feng
    [J]. ARTHRITIS CARE & RESEARCH, 2013, 65 (11) : 1766 - 1774
  • [6] International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
    Miyakis, S
    Lockshin, MD
    Atsumi, T
    Branch, DW
    Brey, RL
    Cervera, R
    Derksen, RHWM
    De Groot, PG
    Koike, T
    Meroni, PL
    Reber, G
    Shoenfeld, Y
    Tincani, A
    Vlachoyiannopoulos, PG
    Krilis, SA
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) : 295 - 306
  • [7] Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis
    Mok, Chi Chiu
    Ho, Ling Yin
    Ying, Shirley King Yee
    Leung, Man Chi
    To, Chi Hung
    Ng, Woon Leung
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (08) : 1070 - 1076
  • [8] Prevalence of the Antiphospholipid Syndrome and Its Effect on Survival in 679 Chinese Patients With Systemic Lupus Erythematosus A Cohort Study
    Mok, Chi Chiu
    Chan, Pak To
    Ho, Ling Yin
    Yu, Ka Lung
    To, Chi Hung
    [J]. MEDICINE, 2013, 92 (04) : 217 - 222
  • [9] A randomized, controlled double-blind study comparing the efficacy and safety of dose-ranging voclosporin with placebo in achieving remission in patients with active lupus nephritis
    Rovin, Brad H.
    Solomons, Neil
    Pendergraft, William F., III
    Dooley, Mary Anne
    Tumlin, James
    Romero-Diaz, Juanita
    Lysenko, Lidia
    Navarra, Sandra V.
    Huizinga, Robert B.
    [J]. KIDNEY INTERNATIONAL, 2019, 95 (01) : 219 - 231
  • [10] Correspondence on 'Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis'
    Xu, Chuanhui
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (12)
1